Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that it has received approval from the National Medical Products Administration for its investigational new drug application for SKB445, a novel ADC drug. SKB445, developed using the company’s OptiDC platform, has shown promising preclinical results for the treatment of advanced solid tumors, marking a significant step forward in the company’s drug development efforts.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, specializing in the development of innovative drugs, particularly in the area of advanced solid tumors. The company utilizes its proprietary OptiDC platform technology to develop novel ADC drugs.
YTD Price Performance: -0.43%
Average Trading Volume: 306,248
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$36.23B
For an in-depth examination of 6990 stock, go to TipRanks’ Stock Analysis page.